Currentblue cross blue shield - tennesseePolicy N/A

Vectra DA Blood Test for Rheumatoid Arthritis

Defines coverage position for the Vectra DA (MBDA) blood test for rheumatoid arthritis, including clinical background, guidelines, and applicable procedure codes; specifies that use of MBDA scores does not meet coverage criteria for this payer.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyVectra DA Blood Test for Rheumatoid Arthritis

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionClaims for the use of a multi-biomarker disease activity score for rheumatoid arthritis (e.g., Vectra DA) do not meet coverage criteria and are subject to denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes to report for this policy.

1Primary Covered/Not-Covered Statement

1Procedure code referenced

Coverage Summary

This policy defines the payer position that the Vectra DA multi-biomarker disease activity (MBDA) test for rheumatoid arthritis does not meet coverage criteria. The MBDA test is a 12‑biomarker serum assay that produces a composite score intended to complement clinical RA disease activity measures and has demonstrated correlation with DAS28‑CRP and prognostic associations for radiographic progression. Guideline assessments and the policy conclusion note that routine clinical utility for management remains inconclusive, supporting a not‑covered determination for this payer.

Not Covered — Provider Impact

Denial Risk

Claims for Vectra DA/MBDA

Claims for the use of a multi-biomarker disease activity score for rheumatoid arthritis (e.g., Vectra DA; CPT 81490) do not meet coverage criteria and are subject to denial.

81490

The Vectra DA (MBDA) test is considered not covered by this payer and claims for this test (CPT 81490) are subject to denial. Clinicians and billing teams should expect denials for claims submitted for the MBDA/Vectra DA assay under this policy.

Background & Evidence

Vectra DA is a commercially available multi‑biomarker disease activity (MBDA) blood test that combines 12 serum biomarkers into a composite score ranging from 1–100 to provide an objective measure of rheumatoid arthritis (RA) disease activity and to complement existing symptom‑based measures. The score categories are defined as ≤29 = low; 29–44 = moderate; >44 = high. Studies have shown the MBDA score correlates significantly with the DAS28‑CRP (r = 0.72; p < 0.001) and has demonstrated prognostic validity for radiographic progression in multiple cohorts, including adjusted MBDA versions that account for age, sex, and adiposity. While MBDA results have been reported to influence treatment decisions in some studies, clinical guidelines have rated Vectra DA as inconclusive for routine adoption, and additional studies are cited as needed to confirm its clinical utility for routine management.

Evidence	Value
Correlation with DAS28-CRP	r = 0.72; p < 0.001
MBDA score categories	≤29 low; 29–44 moderate; >44 high
Impact on treatment decisions (Li et al. 2013)	MBDA results changed treatment plans in 38% of patients

MBDA: Multi‑biomarker disease activity score combining 12 serum biomarkers into a single disease activity score (Vectra DA).

Revision History

policy_statementLatest

The use of a multi-biomarker disease activity score for rheumatoid arthritis (e.g., Vectra DA score) DOES NOT MEET COVERAGE CRITERIA.

test_descriptionLatest

Vectra DA (MBDA) combines 12 serum biomarkers into a composite score from 1–100 intended to complement clinical RA disease activity measures; score categories: ≤29 low, 29–44 moderate, >44 high.

clinical_validityLatest

MBDA correlates with DAS28-CRP (r = 0.72; p < 0.001) and has shown prognostic association with radiographic progression in some studies, but further study needed to confirm clinical utility.

claims_processingLatest

Claims for the use of a multi-biomarker disease activity score for rheumatoid arthritis (e.g., Vectra DA) do not meet coverage criteria and are subject to denial (CPT code 81490).